Movatterモバイル変換

[0]ホーム
URL:

BE2014C068I2 - - Google Patents

Info

Publication number
BE2014C068I2
BE2014C068I2BE2014C068CBE2014C068CBE2014C068I2BE 2014C068 I2BE2014C068 I2BE 2014C068I2BE 2014C068 CBE2014C068 CBE 2014C068CBE 2014C068 CBE2014C068 CBE 2014C068CBE 2014C068 I2BE2014C068 I2BE 2014C068I2
Authority
BE
Belgium
Prior art keywords
present
immunoglobulin
humanized
human
humanized immunoglobulin
Prior art date
Application number
BE2014C068C
Other languages
French (fr)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C068(I2)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm IncfiledCriticalMillennium Pharm Inc
Publication of BE2014C068I2publicationCriticalpatent/BE2014C068I2/fr

Links

Classifications

Landscapes

Abstract

The present invention relates to humanized immunoglobulins having binding specificity for ±4²7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human ±4²7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody. The present invention further relates to a humanized immunoglobulin light chain or heavy chain, isolated nucleic acids comprising a sequence which encodes a humanized immunoglobulin or immunoglobulin chain of the present invention (e.g., a single chain antibody), constructs comprising a nucleic acid of the present invention, and host cells comprising a nucleic acid of the present invention useful in a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in diagnostic and therapeutic applications in humans, for example to control lymphocyte infiltration (including recruitment and/or accumulation) to mucosal tissue.
BE2014C068C1996-08-152014-11-12BE2014C068I2 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US08/700,737US7147851B1 (en)1996-08-151996-08-15Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication NumberPublication Date
BE2014C068I2true BE2014C068I2 (en)2017-09-22

Family

ID=24814673

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BE2014C068CBE2014C068I2 (en)1996-08-152014-11-12

Country Status (19)

CountryLink
US (3)US7147851B1 (en)
EP (2)EP1710314A1 (en)
JP (3)JP4171071B2 (en)
CN (1)CN100406562C (en)
AT (1)ATE321788T1 (en)
AU (1)AU730326C (en)
BE (1)BE2014C068I2 (en)
BR (1)BRPI9711079B1 (en)
CA (1)CA2263106C (en)
DE (1)DE69735596T3 (en)
DK (1)DK0918797T4 (en)
ES (1)ES2262186T5 (en)
IL (3)IL128052A0 (en)
LT (1)LTC0918797I2 (en)
LU (1)LU92596I2 (en)
NZ (1)NZ334226A (en)
PT (1)PT918797E (en)
SI (1)SI0918797T2 (en)
WO (1)WO1998006248A2 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7147851B1 (en)*1996-08-152006-12-12Millennium Pharmaceuticals, Inc.Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en)1997-02-212006-10-17Genentech, Inc.Antibody fragment-polymer conjugates and uses of same
US7964192B1 (en)1997-12-022011-06-21Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidgenic disease
US7790856B2 (en)1998-04-072010-09-07Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)*1997-12-022004-09-07Neuralab LimitedPrevention and treatment of amyloidogenic disease
TWI239847B (en)*1997-12-022005-09-21Elan Pharm IncN-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)1998-04-072008-02-28Guriq BasiHumanized antibodies that recognize beta amyloid peptide
US7090845B2 (en)*1998-05-132006-08-15Genentech, Inc.Diagnosis and treatment of hepatic disorders
AU2011226857B2 (en)*1998-05-132013-09-19Genentech, Inc.Diagnosis and treatment of hepatic disorders
DE69929712T2 (en)*1998-11-252006-10-19The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Alpha-E-beta-7 integrin antagonists as therapeutic agents against inflammatory diseases
CN1332714C (en)*1999-04-222007-08-22比奥根艾迪克Ma公司Method for treating fibrosis by utilizing integrin alpha 4 subunit antagonist
US20010046496A1 (en)2000-04-142001-11-29Brettman Lee R.Method of administering an antibody
AU2006220426B2 (en)*2000-04-142008-10-30Genentech Inc.Method of administering an antibody
US7658924B2 (en)*2001-10-112010-02-09Amgen Inc.Angiopoietin-2 specific binding agents
US7521053B2 (en)*2001-10-112009-04-21Amgen Inc.Angiopoietin-2 specific binding agents
US20060246066A1 (en)*2001-12-172006-11-02Morgan Bryan PCleavable reagents for specific delivery to disease sites
CA2473144C (en)2002-02-052013-05-28Genentech, Inc.Protein purification
MY139983A (en)2002-03-122009-11-30Janssen Alzheimer ImmunotherapHumanized antibodies that recognize beta amyloid peptide
US7323553B2 (en)2002-04-262008-01-29Genentech, Inc.Non-affinity purification of proteins
SI1507556T1 (en)*2002-05-022016-10-28Wyeth Holdings LlcCalicheamicin derivative-carrier conjugates
GB0210121D0 (en)*2002-05-022002-06-12Celltech R&D LtdBiological products
JP2006524039A (en)*2003-01-092006-10-26マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
RU2390350C2 (en)*2003-02-012010-05-27Ньюралаб ЛимитедActive immunisation for creating soluble a-beta antibodies
DK1648940T3 (en)2003-07-282016-08-15Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
EP3192872A1 (en)2003-08-262017-07-19The Regents of the University of Colorado, a body corporateInhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP2135619A1 (en)2003-12-102009-12-23Millennium Pharmaceuticals, Inc.Humanized anti-CCR2 antibodies and methods of use therefor
NZ548702A (en)2004-01-092009-06-26PfizerAntibodies to MAdCAM
US7655229B2 (en)2004-09-022010-02-02Chan Andrew CAnti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en)2004-09-022010-02-16Genentech, Inc.Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
SI2990422T1 (en)2004-09-032018-10-30Genentech, Inc.Humanized anti-beta7 antagonists and uses therefor
JO3000B1 (en)2004-10-202016-09-05Genentech IncAntibody Formulations.
TW200635607A (en)2004-12-152006-10-16Elan Pharm IncHumanized Aβ antibodies for use in improving cognition
MY146381A (en)2004-12-222012-08-15Amgen IncCompositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007151A2 (en)*2005-07-112007-01-18Pfizer LimitedUse of anti-mad-cam antibody for the treatment of emphysema
WO2007007160A2 (en)*2005-07-112007-01-18Pfizer LimitedAnti-madcam antibodies to treat fever
US20070122404A1 (en)*2005-11-172007-05-31O'keefe Theresa LHumanized immunoglobulin reactive with alpha4beta7 integrin
US8784810B2 (en)2006-04-182014-07-22Janssen Alzheimer ImmunotherapyTreatment of amyloidogenic diseases
FR2902799B1 (en)2006-06-272012-10-26Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8569464B2 (en)2006-12-212013-10-29Emd Millipore CorporationPurification of proteins
US8362217B2 (en)2006-12-212013-01-29Emd Millipore CorporationPurification of proteins
WO2008079302A2 (en)2006-12-212008-07-03Millipore CorporationPurification of proteins
ES2426158T3 (en)2007-01-222013-10-21Genentech, Inc. Precipitation with polyelectrolyte and antibody purification
EP2129397B1 (en)*2007-03-022018-10-31Amgen, Inc.Methods and compositions for treating tumor diseases
JP2010521966A (en)*2007-03-202010-07-01ミレニアム・ファーマシューティカルズ・インコーポレイテッド Nucleic acid encoding humanized immunoglobulin that binds to α4β7 integrin
US8003097B2 (en)2007-04-182011-08-23Janssen Alzheimer ImmunotherapyTreatment of cerebral amyloid angiopathy
CN111253484A (en)2007-06-252020-06-09艾斯巴技术-诺华有限责任公司Methods of modifying antibodies and modified antibodies with improved functional properties
EP2586788B1 (en)2007-07-092017-11-29Genentech, Inc.Prevention of disulfide bond reduction during recombinant production of polypeptides
ES2498040T3 (en)*2007-07-272014-09-24Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta antibodies
JO3076B1 (en)2007-10-172017-03-15Janssen Alzheimer ImmunotherapImmunotherapy regimes dependent on apoe status
CL2008003218A1 (en)2007-10-302009-03-06Genentech Inc Method for the purification of an antibody from a composition comprising the antibody and at least one contaminant.
AU2009203369B2 (en)*2008-01-112014-04-03Astellas Pharma Inc.Improved humanized anti-human alpha9-integrin antibody
JO2913B1 (en)2008-02-202015-09-15امجين إنك,Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8999702B2 (en)2008-06-112015-04-07Emd Millipore CorporationStirred tank bioreactor
LT2848625T (en)2008-08-142019-10-10Genentech, Inc.Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2684570A1 (en)2008-09-102014-01-15F. Hoffmann-La Roche AGCompositions and methods for the prevention of oxidative degradation of proteins
US9067981B1 (en)2008-10-302015-06-30Janssen Sciences Ireland UcHybrid amyloid-beta antibodies
US20110020327A1 (en)2008-12-162011-01-27Millipore CorporationPurification of proteins
CN102257122B (en)2008-12-162015-07-29Emd密理博公司Stirred tank reactor and method
CA2752884A1 (en)2009-02-272010-09-02Genentech, Inc.Methods and compositions for protein labelling
AU2013205341B2 (en)*2009-03-202016-05-05Amgen Inc.Alpha-4-beta-7 heterodimer specific antagonist antibody
MX357213B (en)2009-03-202018-06-29Amgen IncAlpha-4-beta-7 heterodimer specific antagonist antibody.
AU2016208453B2 (en)*2009-03-202018-02-22Amgen Inc.Alpha-4-beta-7 heterodimer specific antagonist antibody
KR20170113704A (en)2009-05-132017-10-12젠자임 코포레이션Anti-human cd52 immunoglobulins
EP3760712A1 (en)2009-08-112021-01-06F. Hoffmann-La Roche AGProduction of proteins in glutamine-free cell culture media
SI2473617T1 (en)2009-09-012020-07-31F. Hoffmann-La Roche AgEnhanced protein purification through a modified protein a elution
SI3202785T1 (en)2009-10-262024-08-30F. Hoffmann-La Roche AgMethod for the production of a glycosylated immunoglobulin
WO2011119487A2 (en)2010-03-222011-09-29Genentech, Inc.Compositions and methods useful for stabilizing protein-containing formulations
MX2012012743A (en)2010-05-032012-11-23Genentech IncCompositions and methods useful for reducing the viscosity of protein-containing formulations.
BR112012028977B1 (en)2010-05-172020-05-05Emd Millipore Corp biomolecule purification method by means of stimulus-responsive polymers
HUE030820T2 (en)2010-05-282017-06-28Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
SI2585045T1 (en)2010-06-242019-11-29Hoffmann La RocheCompositions and methods containing alkylgycosides for stabilizing protein-containing formulations
MX2013001267A (en)2010-08-132013-04-10Genentech IncAntibodies to il-1beta and il-18, for treatment of disease.
WO2012030512A1 (en)2010-09-032012-03-08Percivia Llc.Flow-through protein purification process
UA116189C2 (en)*2011-05-022018-02-26Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
UY34054A (en)2011-05-022012-11-30Millennium Pharm Inc FORMULATION FOR ANTI-A ANTIBODY (alpha) 4B (Beta) 7
CA2839917A1 (en)2011-06-242012-12-27The Regents Of The University Of Colorado, A Body CorporateCompositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20200008022A (en)2011-12-222020-01-22제넨테크, 인크.Ion exchange membrane chromatography
US10745468B2 (en)2011-12-222020-08-18Kota Biotherapeutics, LlcCompositions and methods for modified B cells expressing reassigned biological agents
EP2802653A4 (en)*2012-01-102015-09-02Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
EA034583B1 (en)*2012-01-122020-02-21Милленниум Фармасьютикалз, Инк.USES OF ANTI-α4β7 ANTIBODY
KR20200037425A (en)2012-03-272020-04-08제넨테크, 인크.Improved harvest operations for recombinant proteins
CN103374073A (en)*2012-04-262013-10-30中国科学院上海生命科学研究院 Humanized monoclonal antibody that recognizes the activated form of integrin α4β7
WO2013173687A1 (en)2012-05-182013-11-21Genentech, Inc.High-concentration monoclonal antibody formulations
EP2934602B1 (en)2012-12-192019-02-27Genentech, Inc.Methods and compositions for radiohalogen protein labeling
AR095199A1 (en)2013-03-152015-09-30Genzyme Corp ANTI-CD52 ANTIBODIES
MX2017000231A (en)2014-07-092017-06-27Genentech IncPh adjustment to improve thaw recovery of cell banks.
IL251136B (en)2014-10-062022-07-01Chemocentryx Inc Combined treatment of c-c receptor inhibitors type 9 (ccr9) and integrin-blocking anti-alha4beta7 antibodies
US20170327584A1 (en)2014-11-262017-11-16Millennium Pharmaceuticals, Inc.Vedolizumab for the Treatment of Fistulizing Crohn's Disease
EP3237004B1 (en)2014-12-242024-05-08Takeda Pharmaceutical Company LimitedPredicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
MA41636A (en)2015-03-062018-01-09Millennium Pharm Inc METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS
JP6548052B2 (en)*2015-08-112019-07-24国立大学法人大阪大学 antibody
KR20180039726A (en)2015-09-042018-04-18더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 Insulin immunoglobulin fusion protein
EP3397274A1 (en)2015-12-312018-11-07The Regents of the University of Colorado, a body corporateMethods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
EP3430052A2 (en)*2016-03-142019-01-23Millennium Pharmaceuticals, Inc.Method of preventing graft versus host disease
EP3430053A1 (en)*2016-03-142019-01-23Millennium Pharmaceuticals, Inc.Methods of treating or preventing graft versus host disease
WO2017165742A1 (en)2016-03-242017-09-28Millennium Pharmaceuticals, Inc.Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en)2016-03-242017-09-28Millennium Pharmaceuticals, Inc.Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
BR112018070139A2 (en)2016-03-292019-02-05Geltor Inc protein expression in gram-negative bacteria where the ratio of periplasmic volume to cytoplasmic volume is between 0.5: 1 and 10: 1
MA44864A (en)2016-05-042019-03-13Icahn School Med Mount Sinai TRITHERAPY FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASE
WO2017214376A1 (en)*2016-06-102017-12-14Elwha LlcCompositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
WO2017218434A1 (en)2016-06-122017-12-21Millennium Pharmaceuticals, Inc.Method of treating inflammatory bowel disease
WO2018104893A1 (en)2016-12-062018-06-14Glaxosmithkline Intellectual Property Development LimitedAlpha4-beta7 antibodies with incrased fcrn binding and/or half-life
EP3558366A1 (en)2016-12-222019-10-30H. Hoffnabb-La Roche AgMethods and formulations for reducing reconstitution time of lyophilized polypeptides
JP2020517671A (en)2017-04-282020-06-18ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． How to treat disorders in children
SG11202000298VA (en)2017-07-142020-02-27PfizerAntibodies to madcam
US11180541B2 (en)2017-09-282021-11-23Geltor, Inc.Recombinant collagen and elastin molecules and uses thereof
CA3104684A1 (en)2018-07-032020-01-09Bristol-Myers Squibb CompanyMethods of producing recombinant proteins
EP3864127A1 (en)2018-10-102021-08-18Boehringer Ingelheim International GmbHMethod for membrane gas transfer in high density bioreactor culture
US20220098329A1 (en)*2018-11-302022-03-31Memorial Sloan Kettering Cancer CenterHeterodimeric tetravalency and specificity antibody compositions and uses thereof
KR20210145152A (en)2019-04-012021-12-01제넨테크, 인크. Compositions and methods for stabilization of protein-containing formulations
GB2597416A (en)2019-04-122022-01-26Geltor IncRecombinant elastin and production thereof
EP3956358A4 (en)*2019-04-172023-01-25Millennium Pharmaceuticals, Inc.Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
CN118909119A (en)*2019-06-102024-11-08武田药品工业株式会社Antibody purification methods and compositions thereof
TW202112819A (en)*2019-06-102021-04-01美商千禧製藥公司Cell culture methods and compositions for antibody production
WO2021021973A1 (en)2019-08-012021-02-04Bristol-Myers Squibb CompanyMethods of improving protein productivity in fed-batch cell cultures
JP2023542924A (en)2020-09-222023-10-12ブリストル－マイヤーズ スクイブ カンパニー Methods for producing therapeutic proteins
US20250115666A1 (en)2021-08-052025-04-10Bristol-Myers Squibb CompanyCell culture methods for producing therapeutic proteins
WO2023049687A1 (en)2021-09-212023-03-30Bristol-Myers Squibb CompanyMethods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4540289A2 (en)2022-06-162025-04-23Cephalon LLCAnti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024249568A1 (en)2023-05-302024-12-05Paragon Therapeutics, Inc.Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en)2023-06-092024-12-12Takeda Pharmaceutical Company LimitedMethods and compositions for treating ulcerative colitis
CN117777292B (en)*2023-12-282024-10-18天津大学Anti-integrin alpha4β7Nanobody and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE3220049A1 (en)1982-05-271983-12-01Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen KNITTING AND SHOULDER LOCK COMBINATION FOR V-BED FLAT KNITTING MACHINES WITH SLIDING NEEDLES
GB8308235D0 (en)1983-03-251983-05-05Celltech LtdPolypeptides
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
GB8422238D0 (en)1984-09-031984-10-10Neuberger M SChimeric proteins
US4699880A (en)*1984-09-251987-10-13Immunomedics, Inc.Method of producing monoclonal anti-idiotype antibody
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)1986-03-271986-04-30Winter G PRecombinant dna product
DE3883899T3 (en)1987-03-181999-04-22Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
US5258498A (en)*1987-05-211993-11-02Creative Biomolecules, Inc.Polypeptide linkers for production of biosynthetic proteins
US5403919A (en)1987-08-111995-04-04Board Of Trustees Of The Leland Stanford Junior University Stanford UniversityMethod to control leukocyte extravasation
US5538724A (en)1987-08-111996-07-23The Board Of Trustees For The Leland Stanford Junior Univ.Method of control leukocyte extravasation
EP0303463B1 (en)1987-08-111994-11-30The Board Of Trustees Of The Leland Stanford Junior UniversityMethod to control leukocyte extravasation
US5223392A (en)*1988-01-251993-06-29Exocell, Inc.Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (en)1988-02-052000-10-03エル． モリソン，シェリー Antibodies with domain-denaturing constants
WO1990007321A2 (en)1988-12-231990-07-12The Board Of Trustees Of The Leland Stanford Junior UniversityLymphocyte receptor homing sequences and their uses
IL162181A (en)*1988-12-282006-04-10Pdl Biopharma IncA method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)*1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5225538A (en)*1989-02-231993-07-06Genentech, Inc.Lymphocyte homing receptor/immunoglobulin fusion proteins
IL95501A (en)1989-09-011997-04-15Hutchinson Fred Cancer ResInhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en)1989-12-211990-02-28Celltech LtdHumanised antibodies
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
WO1992015683A1 (en)1991-03-061992-09-17MERCK Patent Gesellschaft mit beschränkter HaftungHumanized and chimeric monoclonal antibodies
US5665595A (en)*1991-06-071997-09-09DowelancoImmunoglobulins against insect tissue
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
GB9115364D0 (en)1991-07-161991-08-28Wellcome FoundAntibody
US5871734A (en)1992-01-131999-02-16Biogen, Inc.Treatment for asthma with VLA-4 blocking agents
ATE151642T1 (en)1992-02-121997-05-15Biogen Inc TREATMENT FOR INFLAMMATORY DISEASE OF THE INTESTINAL
US5932214A (en)1994-08-111999-08-03Biogen, Inc.Treatment for inflammatory bowel disease with VLA-4 blockers
AU5732694A (en)1992-12-011994-06-22Protein Design Labs, Inc.Humanized antibodies reactive with cd18
AU5675794A (en)1992-12-151994-07-04Board Of Trustees Of The Leland Stanford Junior UniversityMucosal vascular addressin, dna and expression
DK0678122T3 (en)1993-01-122000-03-06Biogen Inc Recombinant anti-VLA4 antibody molecules
ATE161730T1 (en)1993-02-091998-01-15Biogen Inc ANTIBODIES FOR TREATING INSULIN-DEPENDENT DIABETES
JPH06303990A (en)1993-04-241994-11-01Kanebo LtdMonoclonal antibody, hybridoma capable of producing the same and production of the same antibody
EP0714409A1 (en)1993-06-161996-06-05Celltech Therapeutics LimitedAntibodies
PT804237E (en)1994-01-252006-10-31Elan Pharm Inc HUMANIZED ANTIBODIES AGAINST THE VLA-4 LEUCOCITARY ADHESION MOLECULE
US5840299A (en)1994-01-251998-11-24Athena Neurosciences, Inc.Humanized antibodies against leukocyte adhesion molecule VLA-4
US6551593B1 (en)*1995-02-102003-04-22Millennium Pharmaceuticals, Inc.Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en)*1996-01-042000-03-14Leukosite, Inc.Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en)*1996-08-152006-12-12Millennium Pharmaceuticals, Inc.Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication numberPublication date
IL175570A0 (en)2006-09-05
CN1227607A (en)1999-09-01
EP1710314A1 (en)2006-10-11
NZ334226A (en)2000-10-27
JP4171071B2 (en)2008-10-22
CN100406562C (en)2008-07-30
US7402410B2 (en)2008-07-22
JP2001507210A (en)2001-06-05
US7147851B1 (en)2006-12-12
DK0918797T3 (en)2006-07-31
WO1998006248A2 (en)1998-02-19
SI0918797T1 (en)2006-10-31
JP5166483B2 (en)2013-03-21
CA2263106A1 (en)1998-02-19
JP2010246548A (en)2010-11-04
LU92596I2 (en)2015-01-12
SI0918797T2 (en)2016-01-29
JP4578536B2 (en)2010-11-10
DK0918797T4 (en)2016-01-11
BRPI9711079B1 (en)2017-06-20
ATE321788T1 (en)2006-04-15
AU730326C (en)2005-06-16
US20060292140A1 (en)2006-12-28
DE69735596T3 (en)2016-02-25
BRPI9711079B8 (en)2021-05-25
US20090011464A1 (en)2009-01-08
AU3972897A (en)1998-03-06
WO1998006248A3 (en)1998-05-07
DE69735596D1 (en)2006-05-18
IL128052A (en)2006-08-20
HK1021822A1 (en)2000-07-07
LTC0918797I2 (en)2017-05-10
DE69735596T2 (en)2006-12-21
CA2263106C (en)2010-08-03
EP0918797A2 (en)1999-06-02
PT918797E (en)2006-08-31
EP0918797B1 (en)2006-03-29
JP2008281562A (en)2008-11-20
ES2262186T3 (en)2006-11-16
ES2262186T5 (en)2015-12-11
EP0918797B2 (en)2015-09-23
AU730326B2 (en)2001-03-01
BR9711079A (en)2000-06-06
IL128052A0 (en)1999-11-30

Similar Documents

PublicationPublication DateTitle
BE2014C068I2 (en)
CY1107708T1 (en) HUMAN MONOCLONAL ANTIBODIES TO EPITERNAL GROWTH FACTOR RECEPTOR
BR9507594B1 (en) humanized scfv monoclonal antibody, recombinant nucleic acid molecule and recombinant protein.
GB2250995A (en)Multivalent antigen-binding proteins
WO1999037681A3 (en)Method for producing antibody fragments
ATE504601T1 (en) ANTI-CD3 ANTIBODIES FOR USE TO INDUCE IMMUNOSUPRESSION
EP1362868A3 (en)Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
DE69000338D1 (en) EXPRESSION SYSTEM FOR THE PRODUCTION OF CHIMERIC MONOCLONAL ANTIBODIES.
WO1998033919A3 (en)Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
GR3020610T3 (en)Monoclonal antibodies against tumor associated antigen, their preparation and use
ES2121358T3 (en) HUMANIZED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-4 HUMAN.
WO1998012334A3 (en)Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
RU94045907A (en)Human hiv-antibodies or their fragments, expression casettes, host-cells, pharmaceutical composition, method of protection
[8]ページ先頭
©2009-2025 Movatter.jp